Fonte: European Journal of Clinical Pharmacology. Unidade: FCFRP
Assuntos: BETA-BLOQUEADORES, HIPERTENSÃO, METABOLISMO, IDOSOS, FARMACOCINÉTICA, DOENÇA DE CHAGAS
ABNT
VIEIRA, Carolina Pinto et al. Chronic Chagas disease with low plasma concentrations of IL-6 does not have a major impact on nebivolol glucuronidation. [Carta]. European Journal of Clinical Pharmacology. Heidelberg: Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo. Disponível em: https://doi.org/10.1007/s00228-020-02837-9. Acesso em: 17 out. 2024. , 2020APA
Vieira, C. P., Neves, D. V., Nardotto, G. H. B., Cesarino, E. J., Rocha, A., Zanardi, A. M. C. T., & Lanchote, V. L. (2020). Chronic Chagas disease with low plasma concentrations of IL-6 does not have a major impact on nebivolol glucuronidation. [Carta]. European Journal of Clinical Pharmacology. Heidelberg: Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo. doi:10.1007/s00228-020-02837-9NLM
Vieira CP, Neves DV, Nardotto GHB, Cesarino EJ, Rocha A, Zanardi AMCT, Lanchote VL. Chronic Chagas disease with low plasma concentrations of IL-6 does not have a major impact on nebivolol glucuronidation. [Carta] [Internet]. European Journal of Clinical Pharmacology. 2020 ; 76( 5): 735-737.[citado 2024 out. 17 ] Available from: https://doi.org/10.1007/s00228-020-02837-9Vancouver
Vieira CP, Neves DV, Nardotto GHB, Cesarino EJ, Rocha A, Zanardi AMCT, Lanchote VL. Chronic Chagas disease with low plasma concentrations of IL-6 does not have a major impact on nebivolol glucuronidation. [Carta] [Internet]. European Journal of Clinical Pharmacology. 2020 ; 76( 5): 735-737.[citado 2024 out. 17 ] Available from: https://doi.org/10.1007/s00228-020-02837-9